Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

DSpace/Manakin Repository

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
 
van Bommel, Erik J M; Lytvyn, Yuliya; Perkins, Bruce A; Soleymanlou, Nima; Fagan, Nora M; Koitka-Weber, Audrey; Joles, Jaap A; Cherney, David Z I; van Raalte, Daniël H
(2020) Kidney International, volume 97, issue 4, pp. 631 - 635
(Editorial)
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: SGLT2 inhibition, diabetes, diabetic nephropathy, glomerular hyperfiltration, Nephrology, Editorial, Research Support, Non-U.S. Gov't
DOI: https://doi.org/10.1016/j.kint.2019.12.021
ISSN: 0085-2538
Publisher: Nature Publishing Group
Note: Funding Information: The Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED) trial (NCT02682563) in people with T2D was funded by AstraZeneca and the Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With and Without Renal Hyperfiltration (ATIRMA) trial (NCT01392560) in people with T1D by Boehringer Ingelheim . Editorial and graphical support, supported financially by Boehringer Ingelheim, was provided by Andy Shepherd of Elevate Scientific Solutions.
(Peer reviewed)